Invivyd, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Invivyd is a clinical-stage biopharmaceutical company developing monoclonal antibodies, initially targeting COVID-19. The filing was signed May 9, 2024.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $31.2 million | $27.2 million |
| Selling, general and administrative expense | $14.9 million | $11.0 million |
| Total operating expenses | $46.1 million | $39.1 million |
| Other income, net | $2.6 million | $3.8 million |
| Net loss | $43.5 million | $35.3 million |
| Basic and diluted loss per share | $0.38 | $0.32 |
| Cash used in operating activities | $50.2 million | $41.2 million |
| Cash and cash equivalents, period-end | $189.4 million | $200.6 million at Dec. 31, 2023 |
Gross margin is not meaningful because the company had not generated revenue through March 31, 2024. It expects to begin reporting PEMGARDA product revenue in Q2 2024. No borrowings are reported; balance-sheet liabilities are primarily operating leases and operating payables/accruals. At March 31, current assets were $209.9 million and current liabilities were $36.3 million.
Material changes and financing
- Net loss increased $8.2 million year over year as operating expenses rose $7.0 million and other income fell $1.2 million.
- R&D expense increased $4.0 million, mainly from VYD222 commercial manufacturing and CANOPY trial costs, plus manufacturing work on newly nominated VYD2311. Lower adintrevimab and discovery-related spending partly offset the increases.
- SG&A increased $3.9 million, chiefly from commercialization-related professional and consultant fees and higher personnel costs.
- Operating cash use increased $9.0 million year over year. Financing provided $39.1 million, principally from February’s issuance of 9.0 million shares under the at-the-market facility, generating $39.3 million net proceeds. $34.5 million remained available under that facility at quarter-end.
- Accumulated deficit was $775.6 million. The company reported substantial doubt about its ability to continue as a going concern: without revenue or external financing, current operating plans do not provide sufficient cash beyond one year from issuance of the financial statements.
Business developments, outlook and risks
- The FDA granted PEMGARDA an emergency use authorization on March 22, 2024, for pre-exposure prevention of COVID-19 in certain immunocompromised adults and adolescents. The product is not FDA-approved, and the EUA may be terminated or revoked.
- In May 2024, the company announced plans to seek an EUA for pemivibart to treat mild-to-moderate symptomatic COVID-19 in certain immunocompromised people using a rapid immunobridging pathway. It plans a compact confirmatory trial focused on safety, pharmacokinetics and clinical virology following the anticipated submission.
- VYD2311, nominated in January 2024 and optimized against recent SARS-CoV-2 lineages, is expected to be the next program to enter clinical development. Management also intends to apply its platform to other viral diseases, including influenza.
- Manufacturing commitments to WuXi Biologics include $69.3 million for commercial drug substance and drug product purchases expected to be paid in 2024–2025, plus $24.7 million for materials expected to be paid in 2024. Of the commercial-batch obligation, $18.4 million was already included in accounts payable and accrued expenses.
- A securities class action concerning past statements about ADG20’s effectiveness against Omicron remained pending. The company said it would defend the case; the filing states that outcome and potential materiality could not yet be assessed.
- Key risks include continued losses and need for additional capital, execution of PEMGARDA commercialization, manufacturing and supply dependence, clinical and regulatory uncertainty, changing viral variants, and potential dilution or unfavorable financing terms. Management gave no specific financial guidance or quantified revenue forecast.
Investor verification points
- Track PEMGARDA launch, access, demand and reported Q2 revenue, and confirm the scope and status of any treatment EUA submission.
- Monitor cash burn, financing availability, dilution and management’s plans to address the stated going-concern uncertainty.
- Assess whether manufacturing obligations and inventory align with commercial demand; verify the timing and recoverability of the $69.3 million purchase commitments and capitalized inventory.
- Follow CANOPY, VYD2311’s clinical-development timing, and the securities lawsuit, including its procedural outcome and any potential financial exposure.